A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

NCT01859026 PHASE1 COMPLETED

The main purpose of this study is to find out if the drugs MEK162 and erlotinib (Tarceva) given in combination are safe and have beneficial effects in patients who have NSCLC. The U.S. Food and Drug Administration (FDA) has not approved MEK162 for use to treat NSCLC. Erlotinib is an FDA approved drug for the treatment of Non-Small Cell Lung Cancer.

Details

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	PHASE1
Status	COMPLETED
Enrolment	43
Start date	Mon Dec 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lung Cancer
• Non-Small Cell Lung Cancer

Interventions

• MEK162
• Erlotinib

Countries

United States